Dr David Cutter
Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)
David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined CTSU to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013 he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.
Evidence-based Review on the Use of Proton Therapy in Lymphoma From the Particle Therapy Cooperative Group (PTCOG) Lymphoma Subcommittee.
Tseng YD. et al, (2017), Int J Radiat Oncol Biol Phys
Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study.
Rugbjerg K. et al, (2017), Int J Cancer, 140, 2232 - 2245
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.
van Nimwegen FA. et al, (2017), Blood, 129, 2257 - 2265
Risk of Cerebrovascular Events in 178 962 Five-Year Survivors of Cancer Diagnosed at 15 to 39 Years of Age: The TYACSS (Teenage and Young Adult Cancer Survivor Study).
Bright CJ. et al, (2017), Circulation, 135, 1194 - 1210
Population-Based Long-Term Cardiac-Specific Mortality Among 34 489 Five-Year Survivors of Childhood Cancer in Great Britain.
Fidler MM. et al, (2017), Circulation, 135, 951 - 963